Blog - Page 118 of 5675 - QualityStocks

WednesdayFeb 18, 2026 9:50 am

QualityStocksNewsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Appoints Sidney Braun as CEO of Liora Technologies Europe Subsidiary

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical and med-tech company advancing cancer treatments, announced the appointment of Sidney Braun as Chief Executive Officer of its Liora Technologies Europe Ltd. subsidiary. Braun, who previously facilitated LIXTE’s November 2025 acquisition of Liora’s assets, brings more than 20 years of healthcare operational and strategic advisory experience and will lead advancement of Liora’s LiGHT System, an electronically controlled proton therapy platform designed to enhance tumor treatment. Management said the appointment supports its strategy to scale the technology and pursue a recurring revenue model within the radiotherapy segment of cancer care. To view the…

WednesdayFeb 18, 2026 9:45 am

When Cancer Care Hits a Hardware Wall, One Microcap Is Building Around It

In oncology, the biggest constraints are not always science. They are often the logistics, the cost of specialized infrastructure, and the difficulty of scaling advanced treatment capacity fast enough to meet demand. A Two-Track Strategy: Sensitizing Tumors, Modernizing Delivery LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) is pursuing a model that tries to improve cancer outcomes from two directions at once. On the therapeutic side, the company’s lead asset is LB-100, a clinical-stage compound designed to inhibit protein phosphatase 2A (“PP2A”), a biological target involved in cellular stress response and DNA repair pathways. LIXTE’s stated strategy is not to replace standard…

WednesdayFeb 18, 2026 9:40 am

QualityStocksNewsBreaks – Lahontan Gold Corp. (TSXV: LG) (OTCQB: LGCXF) Reports Additional Oxide Gold and Silver Intercepts at West Santa Fe

This article has been disseminated on behalf of Lahontan Gold Corp. and may include paid advertising. Lahontan Gold (TSXV: LG) (OTCQB: LGCXF) announced additional analytical results from its 2025 maiden drilling program at the West Santa Fe project in Nevada’s Walker Lane, including 48.8 meters grading 0.83 g/t Au Eq in hole WSF25-02R and 45.7 meters grading 0.64 g/t Au Eq in hole WSF25-05R, with mineralization beginning at surface and remaining open to the north and west. Management said the results confirm a 500-by-350-meter surface expression of gold and silver mineralization with thicknesses ranging from approximately 35 to nearly 60…

WednesdayFeb 18, 2026 9:30 am

QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Late-Stage Biotech M&A Trends

Oncotelic Therapeutics (OTCQB: OTLC) announced its placement in an editorial published by BioMedWire, one of more than 75 brands within the Dynamic Brand Portfolio at IBN (InvestorBrandNetwork), highlighting the growing focus in biotech mergers and acquisitions on de-risked, late-stage assets with clinical validation. The article, titled “Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A,” examines how pharmaceutical companies and investors are prioritizing programs with established safety and efficacy data, placing companies such as Oncotelic, with multiple clinical- and late-stage oncology and central nervous system programs, in alignment with current M&A trends as it advances its…

WednesdayFeb 18, 2026 9:29 am

QualityStocksNewsBreaks – Nevada Organic Phosphate Inc. (CSE: NOP; OTCQB: NOPFF) Prepares for 2026 Murdock Mountain Drill Program Expansion

This article has been disseminated on behalf of Nevada Organic Phosphate Inc. and may include paid advertising. Nevada Organic Phosphate (CSE: NOP; OTCQB: NOPFF) announced that field preparations are underway for the continuation of its Murdock Mountain drill program, with mobilization currently estimated for mid- to late-March 2026. The 2026 campaign is designed to extend the successful 2025 program westward, with plans to construct at least five additional drill pads along the remaining five-kilometer strike length and drill multiple holes per pad to further evaluate the continuity, thickness and grade of the 6.6-kilometer phosphate-bearing horizon. The Company said updated climate access modeling suggests heavy equipment access could begin as early…

WednesdayFeb 18, 2026 9:20 am

QualityStocksNewsBreaks – Earth Science Tech, Inc. (OTC: ETST) Reports Fiscal Q3 2026 Revenue Up 14% and Net Income Up 341%

Earth Science Tech (OTC: ETST) reported financial and operational results for the third fiscal quarter ended Dec. 31, 2025, with revenue of $8.4 million, up 14.1% year over year, gross profit of $6.4 million reflecting a 76.3% margin, and net income of $910,000, up 341% from the prior-year period. Adjusted EBITDA totaled $1.2 million, total assets increased to $8.1 million, and the company repurchased and retired 3.7 million shares during the first nine months of fiscal 2026, while ending the quarter with $416,000 in cash, $773,000 in working capital and no bank debt as management cited continued operating leverage and…

WednesdayFeb 18, 2026 9:10 am

QualityStocksNewsBreaks – Datavault AI Inc. (NASDAQ: DVLT) Raises Preliminary FY 2025 Revenue to $38-$40 Million, Reaffirms $200 Million FY 2026 Target

Datavault AI (NASDAQ: DVLT) updated its preliminary, unaudited fiscal 2025 revenue estimate to $38 million to $40 million, exceeding its prior $30 million estimate by up to 33%, with midpoint growth of approximately 1,300% year over year, driven by customer tech-licensing fees and tokenization and monetization services from its Data Science Group. The company also reaffirmed its anticipated fiscal 2026 revenue target of $200 million, representing projected year-over-year growth of 400% to 426%, and said it plans to file its audited 2025 financial results with the SEC next month. To view the full press release, visit https://ibn.fm/Z5sSf About Datavault AI…

WednesdayFeb 18, 2026 9:00 am

SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) Prepares for the U.S. Market by Forming a Subsidiary and Launching Its Navigation and Target Acquisition Application

Disseminated on behalf of SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) and may include paid advertising. SPARC AI recently launched the company’s navigation and target acquisition application on a defense made Tactical Edition smartphone The application provides an on-device software layer that offers GPS-denied navigation as well as laser-free target acquisition that uses the phone’s camera The company is also planning to register a U.S. subsidiary to support participation in U.S. defense procurement pathways and streamline eligibility for bids and tenders SPARC AI (CSE: SPAI) (OTCQB: SPAIF), a next-gen developer of target acquisition systems and navigation software, recently launched a…

TuesdayFeb 17, 2026 3:33 pm

QualityStocksNewsBreaks – Globavend Holdings Limited (NASDAQ: GVH) Reports 42.5% Revenue Growth for Fiscal 2025

Globavend Holdings (NASDAQ: GVH) reported financial results for the year ended Sept. 30, 2025, with revenue rising 42.5% year over year to $23.6 million. The company said it handled an average of 10,394 packages per day, up 69.4% from the prior year, while average daily revenue per freight weight increased 12.7%. Net income totaled $0.68 million. During the year, Globavend established a subsidiary in China and built out corporate infrastructure to support expansion, as management cited capital markets support and a growing pipeline positioning the company for continued revenue growth into 2026 and beyond. To view the full press release, visit https://ibn.fm/MUSnQ About Globavend Holdings Limited Globavend Holdings Limited,…

TuesdayFeb 17, 2026 2:41 pm

QualityStocksNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Completes FDA Type C Meeting for NRX-100 NDA Pathway

NRx Pharmaceuticals (NASDAQ: NRXP) announced completion of an in-person Type C guidance meeting with the U.S. Food and Drug Administration, attended by leadership from the Division of Psychiatry Products, Office of Neuroscience and Center for Drug Evaluation and Research. Based on oral guidance, the company believes it has a path to file a New Drug Application for NRX-100, a preservative-free ketamine formulation, supported by existing adequate and well-controlled trials and confirmatory evidence from more than 65,000 patients in a Real World Evidence dataset, while also seeking a broader indication for treatment-resistant depression with suicidality. The FDA advised that no additional nonclinical or bridging studies would be required, and…

Site Search

Company Search